higenamine has been researched along with Intervertebral Disc Degeneration in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, X; Cao, Z; Hu, L; Li, Y; Liu, S; Lu, F; Yang, L; Zhu, X | 1 |
| Bai, X; Ding, W; Guo, X; Yang, S | 1 |
2 other study(ies) available for higenamine and Intervertebral Disc Degeneration
| Article | Year |
|---|---|
Higenamine mitigates interleukin-1β-induced human nucleus pulposus cell apoptosis by ROS-mediated PI3K/Akt signaling.
Topics: Adrenergic beta-Antagonists; Alkaloids; Apoptosis; Cells, Cultured; Humans; Interleukin-1beta; Intervertebral Disc Degeneration; Nucleus Pulposus; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Tetrahydroisoquinolines | 2021 |
Higenamine inhibits IL-1β-induced inflammation in human nucleus pulposus cells.
Topics: Alkaloids; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Humans; Inflammation; Interleukin-1beta; Intervertebral Disc Degeneration; Nucleus Pulposus; Tetrahydroisoquinolines | 2019 |